162 related articles for article (PubMed ID: 35896894)
1. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo.
Kayabolen A; Akcan U; Özturan D; Ulbegi-Polat H; Sahin GN; Pinarbasi-Degirmenci N; Bayraktar C; Soyler G; Sarayloo E; Nurtop E; Ozer B; Guney-Esken G; Barlas T; Yildirim IS; Dogan O; Karahuseyinoglu S; Lack NA; Kaya M; Albayrak C; Can F; Solaroglu I; Bagci-Onder T
Adv Sci (Weinh); 2022 Sep; 9(27):e2201294. PubMed ID: 35896894
[TBL] [Abstract][Full Text] [Related]
2. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
[TBL] [Abstract][Full Text] [Related]
3. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.
Feng F; Chen J; Zhao J; Li Y; Li M; Sun C
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835049
[TBL] [Abstract][Full Text] [Related]
4. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection.
Kim HK; Cho J; Kim E; Kim J; Yang JS; Kim KC; Lee JY; Shin Y; Palomera LF; Park J; Baek SH; Bae HG; Cho Y; Han J; Sul JH; Lee J; Park JH; Cho YW; Lee W; Jo DG
J Extracell Vesicles; 2022 Jan; 11(1):e12179. PubMed ID: 34982509
[TBL] [Abstract][Full Text] [Related]
5. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
[TBL] [Abstract][Full Text] [Related]
6. Soluble ACE2 as a potential therapy for COVID-19.
Krishnamurthy S; Lockey RF; Kolliputi N
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
[TBL] [Abstract][Full Text] [Related]
7. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
[TBL] [Abstract][Full Text] [Related]
8. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
[TBL] [Abstract][Full Text] [Related]
9. Early shedding of membrane-bounded ACE2 could be an indicator for disease severity in SARS-CoV-2.
Mariappan V; Ranganadin P; Shanmugam L; Rao SR; Balakrishna Pillai A
Biochimie; 2022 Oct; 201():139-147. PubMed ID: 35724946
[TBL] [Abstract][Full Text] [Related]
10. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
Urano E; Itoh Y; Suzuki T; Sasaki T; Kishikawa JI; Akamatsu K; Higuchi Y; Sakai Y; Okamura T; Mitoma S; Sugihara F; Takada A; Kimura M; Nakao S; Hirose M; Sasaki T; Koketsu R; Tsuji S; Yanagida S; Shioda T; Hara E; Matoba S; Matsuura Y; Kanda Y; Arase H; Okada M; Takagi J; Kato T; Hoshino A; Yasutomi Y; Saito A; Okamoto T
Sci Transl Med; 2023 Aug; 15(711):eadi2623. PubMed ID: 37647387
[TBL] [Abstract][Full Text] [Related]
11. Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.
Rahman MM; Hasan M; Ahmed A
Rev Med Virol; 2021 Sep; 31(5):1-12. PubMed ID: 33426683
[TBL] [Abstract][Full Text] [Related]
12. ACE2 Shedding and the Role in COVID-19.
Wang J; Zhao H; An Y
Front Cell Infect Microbiol; 2021; 11():789180. PubMed ID: 35096642
[TBL] [Abstract][Full Text] [Related]
13. Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity.
Havranek B; Chan KK; Wu A; Procko E; Islam SM
J Chem Inf Model; 2021 Sep; 61(9):4656-4669. PubMed ID: 34427448
[TBL] [Abstract][Full Text] [Related]
14. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
Monteil V; Eaton B; Postnikova E; Murphy M; Braunsfeld B; Crozier I; Kricek F; Niederhöfer J; Schwarzböck A; Breid H; Devignot S; Klingström J; Thålin C; Kellner MJ; Christ W; Havervall S; Mereiter S; Knapp S; Sanchez Jimenez A; Bugajska-Schretter A; Dohnal A; Ruf C; Gugenberger R; Hagelkruys A; Montserrat N; Kozieradzki I; Hasan Ali O; Stadlmann J; Holbrook MR; Schmaljohn C; Oostenbrink C; Shoemaker RH; Mirazimi A; Wirnsberger G; Penninger JM
EMBO Mol Med; 2022 Aug; 14(8):e15230. PubMed ID: 35781796
[TBL] [Abstract][Full Text] [Related]
15. Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.
Verstraete MM; Heinkel F; Li J; Cao S; Tran A; Halverson EC; Gene R; Stangle E; Silva-Moreno B; Arrafi S; Bavananthasivam J; Fung M; Eji-Lasisi M; Masterman S; Xanthoudakis S; Dixit S; Babcook J; Clavette B; Fogg M; Escobar-Cabrera E
MAbs; 2023; 15(1):2212415. PubMed ID: 37229608
[TBL] [Abstract][Full Text] [Related]
16. Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection.
Maiti BK
J Hum Hypertens; 2022 May; 36(5):488-492. PubMed ID: 34773078
[TBL] [Abstract][Full Text] [Related]
17. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Wallentin L; Lindbäck J; Eriksson N; Hijazi Z; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Yusuf S; Oldgren J; Siegbahn A
Eur Heart J; 2020 Nov; 41(41):4037-4046. PubMed ID: 32984892
[TBL] [Abstract][Full Text] [Related]
19. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
20.
Wang H; Li C; Obadan AO; Frizzell H; Hsiang TY; Gil S; Germond A; Fountain C; Baldessari A; Roffler S; Kiem HP; Fuller DH; Lieber A
Hum Gene Ther; 2022 Apr; 33(7-8):389-403. PubMed ID: 35057635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
